VSTM biotech catalysts & pipeline

VERASTEM INC · Data as of 2026-10-25

Upcoming catalysts

VS-7375 (GFH375) — FDA meeting

Late 2026

Plan to meet with the FDA before the end of the year to review Phase 3 pivotal trial designs in 1L mCRC (TARGET-D 303) and 1L advanced NSCLC (TARGET-D 302).

Source filing

VS-7375 (GFH375) — Clinical data readout

October

Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October

Source filing

VS-7375 (GFH375) — Initial data

in Q1 2027

Expect to report initial data from the 1L mPDAC combination with GnP in Q1 2027.

Source filing

VS-7375 (GFH375) — Initial data

in Q2 2027

Plan to report initial data from Phase 2 TARGET-D 201 2L PDAC in Q2 2027;

Source filing

avutometinib + defactinib — Topline data

mid-2027

Expect to report topline readout of primary endpoint by mid-2027

Source filing

VS-7375 (GFH375) — Initial data

H2 2027

expect to report initial data from the Phase 2 TARGET-D 202 2L NSCLC and TARGET-D 203 2L CRC trials in the 2H of 2027.

Source filing

VS-7375 (GFH375) — Initial data

H2 2027

expect to report initial data from the Phase 2 TARGET-D 202 2L NSCLC and TARGET-D 203 2L CRC trials in the 2H of 2027.

Source filing

Explore the free biotech catalyst calendar